| Ifosfamide in the Pediatric Malignant Solid Tumors |
|
Sang Wook Choi |
|
Department of Pediatrics, Korea Cancer Center Hospital, Seoul, Korea |
| 소아 악성 고형종양에 대한 Ifosfamide의 효과 |
|
최상욱 |
|
원자력병원 소아과 |
|
|
|
|
| Abstract |
|
Ifosfamide (IFO), one of a number of alkylating agents, has been given with Adriamycin (ADR) or Etopsoide (VP-16) to the thirteen malignant solid tumor patients (five neuroblastoma, six osteosarcoma, one rhabdomyosarcoma, one leigomyosarcoma). IFO 1.8g/m2/d was given for an hour with mensa uroprotection for the consecutive five days. All but two relapsed patients had response. The number of courses were ranged from one to seven, and the internal between them was 3-4 weeks. Most patients tolerated the treatment well. The response was CR 1, PR 9, and the total response rate was 76.8%. The major toxicity was mild to moderate degree of naused and vomiting (84.6%), ketonuria (84.6%), anemia (69.2%) leukopenia (53.8%), proteinurial (46.2%), thrombocytopenia (38.5%), fever (38.5%), hepatotoxicity (15.4%) and convulsion (15.4%). One patient developed transient convulsive disorder, but hemorrhagic cystitis was not found. Although it is a study in the single instituion with small number of patients, IFO may be a promisng first line agent to the pediatric malignant solid tumor. |
| Key Words:
Ifosfamide, Solid tumors, Toxicity |
|
PDF Links
Download Citation
